ClinicalTrials.gg
RecruitingNCT06676527Updated Nov 16, 2026

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

An observational study in Neoplasms, Kidney Neoplasms and Urologic Neoplasms, sponsored by Jinling Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionCarcinoma, Renal CellRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Renal Cell
Why
  1. The study's listed conditions name Carcinoma, Renal Cell, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jinling Hospital, China · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
39
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Planned enrollment
44th of 45
39 · median 300
Started
2024
with 32 others
Observational
45 of 235
25 open now
Primary completion
2027-03
later than 75 of 141 live
Registered
147th of 235
by date
Lead sponsor
9 of 235
Jinling Hospital, China

Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 44th largest by planned enrollment of the 45 observational ones that give a count, is one of 33 that started in 2024, is one of 45 observational ones, reaches primary completion later than 75 of the 141 other live ones, and was the 147th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.

Read the detailed description

This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted. Vorolanib is a new generation of multi-target kinase inhibitors with a new chemical structure, which can inhibit tumor angiogenesis and growth, and is used in the treatment of various cancers. This multicenter, single-arm, open-labelled observational study is designed to include patients who meet the requirements for using vorolanib as a second-line treatment for renal cell carcinoma. For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.

03

Conditions studied

  • Neoplasms
  • Kidney Neoplasms
  • Urologic Neoplasms
  • Urogenital Neoplasms
  • Female Urogenital Diseases
  • Male Urogenital Diseases
  • Urogenital Diseases
  • Kidney Diseases
  • Urologic Diseases
  • Carcinoma
  • Renal Cell Cancer
  • Carcinoma, Renal Cell
  • Antineoplastic Agents

Keywords

  • observational study
  • clear cell Renal Cell Carcinoma
  • TKIs
04

In context

Carcinoma, Renal Cell Reclassified

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

This study's planned enrollment of 39 is below the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Jinling Hospital, China is the lead sponsor of 131 studies on the registry; 35 are open to participants now.

Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects clinically diagnosed with advanced unresectable or metastatic renal cell carcinoma. After receiving at least one systemic therapy (including TKIs or TKIs combined with ICIs, including but not limited to axitinib, sunitinib, sorafenib, pembrolizumab, etc.), subjects reach PD as assessed by RECIST v1.1 and switch to second-line treatment options including vorolanib.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects have fully understood and voluntarily signed the form (ICF);
  • 18-80 years old (at the time of signing the informed consent); Both men and women; PS score: 0-1;
  • Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent renal cell carcinoma dominated by clear cell components;
  • According to (version 1.1), there are targets that are considered to be observable;
  • The main organs function well.

Exclusion criteria

Exclusion Criteria:

  • A history of other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);
  • Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical drug or device therapy within 4 weeks prior to the initial study;
  • Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;
  • A history of severe drug allergy, including but not limited to antibody drugs;
  • Patients with for immunotherapy restart;
  • A known history of allogeneic organ transplantation and hematopoietic stem cell transplantation may require long-term adrenal therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;
  • Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, 5.0 level 0-1 (except for alopecia), or levels specified in inclusion/exclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;
  • Have central nervous system and/or cancerous meningitis;
  • Known history of liver disease, including those infected with viral hepatitis activity;
  • Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);
  • Patients with any severe and/or uncontrolled disease;
  • Renal failure requires hemodialysis or peritoneal dialysis;
  • Have or have a suspected active disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
  • History of vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;
  • Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;
  • Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
39 participants (estimated)
Target follow-up
12 Weeks
Patient registry
Yes

Groups and cohorts

  • Experimental cohort.

    Subjects who progressed after first-line treatment and switched to second-line treatment regimens including vorolanib. The first-line treatment which patients received can be other tyrosine kinase inhibitors (TKIs) or TKIs combined with immunotherapy drugs. Provided vorolanib is contained in the second-line regimen, the patient then can be considered for inclusion in the study.

    Other: Follow-up study of the treated cohort

Interventions

  • OtherFollow-up study of the treated cohort

    For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.

07

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time frame: From enrollment to the end of treatment at 12 weeks.

  2. Treatment Related Adverse Events (TRAEs)

    Time frame: From enrollment to up to 90 days after treatment at 12 weeks or reported.

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From enrollment to the end of treatment at 12 weeks.

  2. Objective Response Rate (ORR)

    Time frame: From enrollment to the end of treatment at 12 weeks.

  3. Disease Control Rate (DCR)

    Time frame: From enrollment to the end of treatment at 12 weeks.

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.

Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's planned 30 months is below that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2026 → Mar 2027 and completion Sep 2026 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 6, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Mar 1, 2027was Sep 2026
CompletionEst.
Mar 1, 2028was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Mar 1, 2027
Nov 16, 2026
Study completion
Sep 1, 2026→Mar 1, 2028
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Sep 1, 2026→Mar 1, 2027
    Study completion Sep 1, 2026→Mar 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06676527
Responsible party
Le Qu (Associate chief urologist, Jinling Hospital, China) — Principal investigator
First posted
Nov 6, 2024
Start date
Sep 1, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Le Qu, M. D.
Contact
septsoul@hotmail.com
+86 15720625951
Yuxiu Liu, M. D.
study chair · Jinling Hospital, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion